Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis

Stephen A. Obstbaum, George A. Cioffi, Guenther K. Krieglstein, M. Brian Fennerty, Albert Alm, Makoto Araie, Roberto G. Carassa, Erik L. Greve, Roger A. Hitchings, Paul L. Kaufman, Yoshiaki Kitazawa, Prin Rojana Pongpun, Remo Susanna, Martin B. Wax, Thom J. Zimmerman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. Objectives: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a "gold standard" medical therapy that reflects new treatment advances and established therapeutic goals. Methods: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. Results: The terms connoting a gold standard therapy were found in only 258 of ∼368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)--lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. Conclusions: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas.

Original languageEnglish (US)
Pages (from-to)2102-2120
Number of pages19
JournalClinical Therapeutics
Volume26
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Glaucoma
Therapeutics
Intraocular Pressure
Ophthalmology
Tachyphylaxis
Benchmarking
Patient Compliance
Optic Nerve
Visual Fields
MEDLINE
Primary Open Angle Glaucoma

Keywords

  • Beta-adrenergic blockers
  • Evidence-based medicine
  • Gold standard
  • Intraocular pressure
  • Open-angle glaucoma
  • Prostaglandin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Obstbaum, S. A., Cioffi, G. A., Krieglstein, G. K., Fennerty, M. B., Alm, A., Araie, M., ... Zimmerman, T. J. (2004). Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis. Clinical Therapeutics, 26(12), 2102-2120. https://doi.org/10.1016/j.clintera.2004.12.007

Gold standard medical therapy for glaucoma : Defining the criteria identifying measures for an evidence-based analysis. / Obstbaum, Stephen A.; Cioffi, George A.; Krieglstein, Guenther K.; Fennerty, M. Brian; Alm, Albert; Araie, Makoto; Carassa, Roberto G.; Greve, Erik L.; Hitchings, Roger A.; Kaufman, Paul L.; Kitazawa, Yoshiaki; Pongpun, Prin Rojana; Susanna, Remo; Wax, Martin B.; Zimmerman, Thom J.

In: Clinical Therapeutics, Vol. 26, No. 12, 12.2004, p. 2102-2120.

Research output: Contribution to journalArticle

Obstbaum, SA, Cioffi, GA, Krieglstein, GK, Fennerty, MB, Alm, A, Araie, M, Carassa, RG, Greve, EL, Hitchings, RA, Kaufman, PL, Kitazawa, Y, Pongpun, PR, Susanna, R, Wax, MB & Zimmerman, TJ 2004, 'Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis', Clinical Therapeutics, vol. 26, no. 12, pp. 2102-2120. https://doi.org/10.1016/j.clintera.2004.12.007
Obstbaum, Stephen A. ; Cioffi, George A. ; Krieglstein, Guenther K. ; Fennerty, M. Brian ; Alm, Albert ; Araie, Makoto ; Carassa, Roberto G. ; Greve, Erik L. ; Hitchings, Roger A. ; Kaufman, Paul L. ; Kitazawa, Yoshiaki ; Pongpun, Prin Rojana ; Susanna, Remo ; Wax, Martin B. ; Zimmerman, Thom J. / Gold standard medical therapy for glaucoma : Defining the criteria identifying measures for an evidence-based analysis. In: Clinical Therapeutics. 2004 ; Vol. 26, No. 12. pp. 2102-2120.
@article{0fa891d8df5047b78e784c2f590fd6df,
title = "Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis",
abstract = "Background: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. Objectives: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a {"}gold standard{"} medical therapy that reflects new treatment advances and established therapeutic goals. Methods: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. Results: The terms connoting a gold standard therapy were found in only 258 of ∼368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)--lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. Conclusions: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas.",
keywords = "Beta-adrenergic blockers, Evidence-based medicine, Gold standard, Intraocular pressure, Open-angle glaucoma, Prostaglandin",
author = "Obstbaum, {Stephen A.} and Cioffi, {George A.} and Krieglstein, {Guenther K.} and Fennerty, {M. Brian} and Albert Alm and Makoto Araie and Carassa, {Roberto G.} and Greve, {Erik L.} and Hitchings, {Roger A.} and Kaufman, {Paul L.} and Yoshiaki Kitazawa and Pongpun, {Prin Rojana} and Remo Susanna and Wax, {Martin B.} and Zimmerman, {Thom J.}",
year = "2004",
month = "12",
doi = "10.1016/j.clintera.2004.12.007",
language = "English (US)",
volume = "26",
pages = "2102--2120",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "12",

}

TY - JOUR

T1 - Gold standard medical therapy for glaucoma

T2 - Defining the criteria identifying measures for an evidence-based analysis

AU - Obstbaum, Stephen A.

AU - Cioffi, George A.

AU - Krieglstein, Guenther K.

AU - Fennerty, M. Brian

AU - Alm, Albert

AU - Araie, Makoto

AU - Carassa, Roberto G.

AU - Greve, Erik L.

AU - Hitchings, Roger A.

AU - Kaufman, Paul L.

AU - Kitazawa, Yoshiaki

AU - Pongpun, Prin Rojana

AU - Susanna, Remo

AU - Wax, Martin B.

AU - Zimmerman, Thom J.

PY - 2004/12

Y1 - 2004/12

N2 - Background: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. Objectives: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a "gold standard" medical therapy that reflects new treatment advances and established therapeutic goals. Methods: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. Results: The terms connoting a gold standard therapy were found in only 258 of ∼368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)--lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. Conclusions: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas.

AB - Background: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. Objectives: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a "gold standard" medical therapy that reflects new treatment advances and established therapeutic goals. Methods: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. Results: The terms connoting a gold standard therapy were found in only 258 of ∼368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)--lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. Conclusions: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas.

KW - Beta-adrenergic blockers

KW - Evidence-based medicine

KW - Gold standard

KW - Intraocular pressure

KW - Open-angle glaucoma

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=20144372782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144372782&partnerID=8YFLogxK

U2 - 10.1016/j.clintera.2004.12.007

DO - 10.1016/j.clintera.2004.12.007

M3 - Article

C2 - 15823774

AN - SCOPUS:20144372782

VL - 26

SP - 2102

EP - 2120

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 12

ER -